

Supplemental Online Content

Amarenco P, Denison H, Evans SR, et al; the THALES Steering Committee and Investigators. Ticagrelor added to aspirin in acute ischemic stroke or transient ischemic attack in prevention of disabling stroke: a randomized clinical trial. *JAMA Neurol*. Published online November 7, 2020. doi:10.1001/jamaneurol.2020.4396

eFigure 1. Flow diagram

eTable 1. mRS csore at day 30

eTable 2. Ordinal analysis of ischemic stroke


eTable 3. Baseline predictors of disabling stroke

eFigure 2. Primary outcome event with mRS >1 and mRS 0-1

eFigure 3. Recurrent stroke event with mRS >1, mRS>2, and mRS>3

This supplemental material has been provided by the authors to give readers additional information about their work.

eFigure 1. Flow Diagram of Study Participants



e Table 1. mRS score at day 30

		Ticagrelor (N=5523)	Placebo (N=5493)
mRS score	0	2020 (36.6%)	1964 (35.8%)
	1	2116 (38.3%)	2126 (38.7%)
	2	755 (13.7%)	755 (13.7%)
	3	307 (5.6%)	302 (5.5%)
	4	168 (3.0%)	182 (3.3%)
	5	21 (0.4%)	24 (0.4%)
	6	36 (0.7%)	27 (0.5%)
	Missing	100 (1.8%)	113 (2.1%)


e Table 2. Ordinal analysis of ischemic stroke.

	Ticagrelor (N=5523)	Placebo (N=5493)			
Variable	Patients with events (%)	Patients with events (%)	Odds ratio	95% CI	P value
No subsequent ischemic stroke	5210 (95.2%)	5100 (93.9%)	0.77	0.65- 0.91	0.002
Subsequent ischemic stroke, mRS=0	15 (0.3%)	15 (0.3%)			
Subsequent ischemic stroke, mRS=1	53 (1.0%)	72 (1.3%)			
Subsequent ischemic stroke, mRS=2	51 (0.9%)	57 (1.0%)			
Subsequent ischemic stroke, mRS=3	51 (0.9%)	70 (1.3%)			
Subsequent ischæmic stroke, mRS=4	69 (1.3%)	90 (1.7%)			
Subsequent ischemic stroke, mRS=5	13 (0.2%)	16 (0.3%)			
Subsequent ischemic stroke, mRS=6	10 (0.2%)	10 (0.2%)			

e Table 3. Baseline predictors of disabling stroke (stroke with mRS>1) or death (multivariable analysis)

Characteristics	OR (95% CI)	p-value
Index event: ischemic stroke NIHSS>3 vs TIA	3.98 (2.54,6.25)	<.0001
Ipsilateral stenosis \geq 30%	2.05 (1.68,2.50)	<.0001
Asian race	1.93 (1.55,2.41)	<.0001
Age (per 5 years)	1.10 (1.05,1.16)	<.0001
Systolic blood pressure (per 5 units)	1.06 (1.04,1.09)	<.0001
Diabetes	1.43 (1.17,1.75)	0.0005
Dyslipidemia	0.81 (0.66-0.99)	0.0387
Randomized to ticagrelor (vs placebo)	0.82 (0.68,0.99)	0.0429
Index event: ischemic stroke NIHSS \leq 3 vs TIA	1.91 (1.22,3.00)	0.7545

e Figure 2. Number of patients with primary outcome event with mRS >1 and mRS 0-1 in ticagrelor and placebo groups



e Figure 3. Number of patients with recurrent stroke event with mRS >1, mRS>2, and mRS>3

